157 related articles for article (PubMed ID: 28861636)
1. Self-perception of fracture risk: what can it tell us?
Litwic AE; Compston JE; Wyman A; Siris ES; Gehlbach SH; Adachi JD; Chapurlat R; Díez-Pérez A; LaCroix AZ; Nieves JW; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Silverman S; Watts NB; Greenspan SL; March L; Gregson CL; Cooper C; Dennison EM;
Osteoporos Int; 2017 Dec; 28(12):3495-3500. PubMed ID: 28861636
[TBL] [Abstract][Full Text] [Related]
2. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study.
Gregson CL; Dennison EM; Compston JE; Adami S; Adachi JD; Anderson FA; Boonen S; Chapurlat R; Díez-Pérez A; Greenspan SL; Hooven FH; LaCroix AZ; Nieves JW; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Silverman S; Siris ES; Watts NB; Wyman A; Cooper C;
Osteoporos Int; 2014 Jan; 25(1):85-95. PubMed ID: 23884437
[TBL] [Abstract][Full Text] [Related]
3. Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW).
Siris ES; Gehlbach S; Adachi JD; Boonen S; Chapurlat RD; Compston JE; Cooper C; Delmas P; Díez-Pérez A; Hooven FH; Lacroix AZ; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Sambrook P; Silverman S; Watts NB; Wyman A; Greenspan SL
Osteoporos Int; 2011 Jan; 22(1):27-35. PubMed ID: 20358360
[TBL] [Abstract][Full Text] [Related]
4. Low self-awareness of osteoporosis and fracture risk among postmenopausal women.
Langer FW; da Silveira Codevilla AA; Bringhenti R; Dal Osto LC; Campos TR; Martins TT; Barin AE; Rigo PH; Boufleuer ND; Santinon SF; Kipper K; Rodrigues J; Premaor MO
Arch Osteoporos; 2016 Dec; 11(1):27. PubMed ID: 27503622
[TBL] [Abstract][Full Text] [Related]
5. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
Osteoporos Int; 2017 Aug; 28(8):2485-2494. PubMed ID: 28536737
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).
Díez-Pérez A; Adachi JD; Adami S; Anderson FA; Boonen S; Chapurlat R; Compston JE; Cooper C; Gehlbach SH; Greenspan SL; Hooven FH; LaCroix AZ; Nieves JW; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Silverman S; Siris ES; Wyman A; Rushton-Smith SK; Watts NB;
J Bone Miner Res; 2014 Jan; 29(1):260-7. PubMed ID: 23794198
[TBL] [Abstract][Full Text] [Related]
7. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
Wilk A; Sajjan S; Modi A; Fan CP; Mavros P
Osteoporos Int; 2014 Dec; 25(12):2777-86. PubMed ID: 25112720
[TBL] [Abstract][Full Text] [Related]
8. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.
Sanfélix-Genovés J; Sanfélix-Gimeno G; Peiró S; Hurtado I; Fluixà C; Fuertes A; Campos JC; Giner V; Baixauli C
Osteoporos Int; 2013 Mar; 24(3):1045-55. PubMed ID: 22618269
[TBL] [Abstract][Full Text] [Related]
10. Systematic screening using FRAX
Parsons CM; Harvey N; Shepstone L; Kanis JA; Lenaghan E; Clarke S; Fordham R; Gittoes N; Harvey I; Holland R; Redmond NM; Howe A; Marshall T; Peters TJ; Torgerson D; O'Neill TW; McCloskey E; Cooper C;
Osteoporos Int; 2020 Jan; 31(1):67-75. PubMed ID: 31606826
[TBL] [Abstract][Full Text] [Related]
11. Obesity is not protective against fracture in postmenopausal women: GLOW.
Compston JE; Watts NB; Chapurlat R; Cooper C; Boonen S; Greenspan S; Pfeilschifter J; Silverman S; Díez-Pérez A; Lindsay R; Saag KG; Netelenbos JC; Gehlbach S; Hooven FH; Flahive J; Adachi JD; Rossini M; Lacroix AZ; Roux C; Sambrook PN; Siris ES;
Am J Med; 2011 Nov; 124(11):1043-50. PubMed ID: 22017783
[TBL] [Abstract][Full Text] [Related]
12. Use of antiosteoporotic medication in the Danish ROSE population-based screening study.
Høiberg MP; Rubin KH; Holmberg T; Rothmann MJ; Möller S; Gram J; Bech M; Brixen K; Hermann AP
Osteoporos Int; 2019 Jun; 30(6):1223-1233. PubMed ID: 30911782
[TBL] [Abstract][Full Text] [Related]
13. Extensive undertreatment of osteoporosis in older Swedish women.
Lorentzon M; Nilsson AG; Johansson H; Kanis JA; Mellström D; Sundh D
Osteoporos Int; 2019 Jun; 30(6):1297-1305. PubMed ID: 30805678
[TBL] [Abstract][Full Text] [Related]
14. Self-perceived facture risk: factors underlying women's perception of risk for osteoporotic fractures: the Risk-Stratified Osteoporosis Strategy Evaluation study (ROSE).
Rothmann MJ; Ammentorp J; Bech M; Gram J; Rasmussen OW; Barkmann R; Glüer CC; Hermann AP
Osteoporos Int; 2015 Feb; 26(2):689-97. PubMed ID: 25361616
[TBL] [Abstract][Full Text] [Related]
15. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
Liu J; Guo H; Rai P; Pinto L; Barron R
Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
[TBL] [Abstract][Full Text] [Related]
16. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study.
Rubin KH; Rothmann MJ; Holmberg T; Høiberg M; Möller S; Barkmann R; Glüer CC; Hermann AP; Bech M; Gram J; Brixen K
Osteoporos Int; 2018 Mar; 29(3):567-578. PubMed ID: 29218381
[TBL] [Abstract][Full Text] [Related]
18. Self-perceived Fracture Risk in the Global Longitudinal Study of Osteoporosis in Women: Its Correlates and Relationship with Bone Microarchitecture.
Litwic AE; Westbury LD; Carter S; Ward KA; Cooper C; Dennison EM
Calcif Tissue Int; 2020 Jun; 106(6):625-636. PubMed ID: 32140759
[TBL] [Abstract][Full Text] [Related]
19. Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
Gehlbach S; Hooven FH; Wyman A; Diez-Perez A; Adachi JD; Luo X; Bushmakin AG; Anderson FA;
PLoS One; 2013; 8(12):e82840. PubMed ID: 24376589
[TBL] [Abstract][Full Text] [Related]
20. Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data.
Cui L; He T; Jiang Y; Li M; Wang O; Jiajue R; Chi Y; Xu Q; Xing X; Xia W
Osteoporos Int; 2020 Feb; 31(2):307-316. PubMed ID: 31754756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
